Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Heidelberg Pharma AG published its financial report on the first six months of 2019
Expedeon AG announced that the Annual General Meeting held in Heidelberg yesterday, July 09, 2019, approved all management proposals.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, announced preliminary financial results for the quarter ended June 30, 2019.
Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that it will release financial results for the second quarter 2019 after the close of trading on Tuesday, August 6.
Global Blood Therapeutics, Inc. announced that on July 1, 2019, the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the company’s common stock with a per share exercise price of $53.93 and restricted stock units for an aggregate of 31,700 shares of the company’s common stock.
Immutep Limited, an Australian biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has announced an equity financing to raise gross proceeds of approximately A$10 million.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH
$103 million raised in Series E expansion, including a new U.S.-based institutional investor, brings total Series E proceeds to $303 million